https://www.auctoresonline.org/article/tyrosine-kinase-inhibitor-associated-aplastic-anemia--a-lethal-adverse-effect-and-its-management-difficulties

SLGT2 inhibitors are antihyperglycemic drugs that block sodium-glucose cotransporter 2 and increase glucosuria by inhibiting renal glucose reabsorption. The fact that they were first identified as useful in diabetes mellitus for this reason, i.e., reduced glucose reuptake by the proximal tubule of the kidney in preventing hyperglycemia is disappointing. A recent research study also suggested these agents may be relevant to depression treatments. Decreased mortality rates and shorter hospital stays have been reported upon administration of these drugs. Moreover, SGLT2 inhibitors take a toll on the renal system, thus warranting more scrutiny over their effect on it. The management of diabetes has seen these drugs coming up as an important class of antihyperglycemic agents. Additionally, scientific studies have recently demonstrated that SGLT2 are effective in the management of heart failure and can considerably reduce both death risk and durations of hospitalization for heart failure patients. Through this discovery, new researches and clinical trials can be done. Nevertheless, they don’t affect kidney diseases because they only change renal glucose reabsorption. Hence, more research is necessary to understand better how much effects on kidney function and related physiological changes that may occur.